Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by JDavenporton Jun 15, 2022 12:05pm
115 Views
Post# 34758323

RE:RE:RE:RE:(TSXV:BTI.V; OTCQB:BIOAF): 4th Quarter/YE Statements

RE:RE:RE:RE:(TSXV:BTI.V; OTCQB:BIOAF): 4th Quarter/YE StatementsI know who the two contract disputes were with but I can't say who they were. KayakerBC is correct, they do not reference partners and both are old news.

When the trolls, by admission, don't read posts longer than a sentence ir two and they then try to isolate an issue out of context, they do not reflect at all on the increasing complexity of what we know and don't know about Bioasis.

Bioasis is getting increasingly difficult to assess. For instance, my questions and concerns about disclosures are not meant to infer that the answers are negative. They infer that the answers are unknown, but could be completely positive. The market hates uncertainty.

As I stated about the Chiesi deal, any delays could be related to Covid and the delayed FDA inspections of Protalix manufacuring facilities and processes, delaying FDA approval of PRX-102. It would make sense for Chiesi to hold off on an xB3 version of PRX-102 until PRX-102 is approved. If PRX-102 is ultimately not approved, which would be a major surprise, then an xB3 version of it or any other drug made by Protalix with ProCellEx could be very unlikely.

Finallytherock just posted a poorly informed opinion about Chiesi and misrepresented my question as a negative statement. I will address that type of trolling. He doesn't have enough knowledge to comment on complex subjects. Otherwise, I don't care what he says about me. Personal attacks are just part of the social media world. Cowards always are big mouths when they're anonymous.

jd
<< Previous
Bullboard Posts
Next >>